ClinicalTrials.gg
CompletedNCT01332149Updated Jan 28, 2021Results posted

Study To Evaluate Efficacy, Safety And Tolerability Of Lyrica In Patients With Painful Diabetic Peripheral Neuropathy

A Phase 3 interventional study of Pregabalin and Placebo matched with pregabalin in Diabetic Neuropathy, Painful, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 30 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-28.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
626
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing pregabalin in Diabetic Neuropathies — 1 open to participants now, 1 under way, 1 of them phase 3. Pregabalin · Diabetic Neuropathies.

Enrollment
3rd of 17
626 · median 241
Started
2011
the only one that year
Phase 3
10 of 17
1 open now
Registered
15th of 17
by date
Lead sponsor
9 of 17
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 17 studies testing pregabalin in Diabetic Neuropathies, this one is the 3rd largest by enrollment, is the only one that started in 2011, is one of 10 in phase 3, and was the 15th registered.

Diabetic Neuropathies

539 studies on the registry are indexed under Diabetic Neuropathies; 80 are open to participants now.

Browse Diabetic Neuropathies studies →

Open to participants now

1 of the 17 studies testing pregabalin in Diabetic Neuropathies is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About pregabalin

Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 52 Diabetic Neuropathies studies recruiting now, 21 (40%) set no upper age limit and 24 (46%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing pregabalin in Diabetic Neuropathies, or all of them as a file.
02

Study summary

Pregabalin has proven effective in previous clinical trails in other countries in relieving neuropathic pain associated with postherpetic neuralgia and painful diabetic neuropathy.

This study is being conducted according to China registration requirement to submit a reapplication with new local diabetic peripheral neuropathy study as a commitment plus the existing data to apply for Lyrica "pain associated with postherpetic neuralgia" indication after Lyrica "pain associated with postherpetic neuralgia" is approved.

03

Conditions studied

  • Diabetic Neuropathy, Painful

Keywords

  • Diabetic Neuropathies
  • Pain
  • Efficacy of pregabalin
  • Placebo controlled
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects aged 18 years or older
  • Diagnosis of painful, distal, symmetrical, sensorimotor polyneuropathy which is due to diabetes mellitus (Type 1 or 2), and symptoms of painful diabetic neuropathy for 6 months to 5 years (inclusive).
  • At the baseline and randomization visits, a score of ≥50 mm on the Visual Analogue Scale, at randomization, subjects must have completed at least 5 daily pain interference diaries, and have an average daily pain score of ≥5 over the past 7 days.
  • Patient who are willing and capable to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
  • Women of are willing to use during study.

Exclusion criteria

Exclusion Criteria:

  • Subjects with more than 30% decrease on the Pain Visual Analog Scale at randomization as compared to screening; and during the 1 week screening period, with more than one pain score \<3 in pain scores.
  • Subject has other kinds of neurological disorder, pain of other reason, or skin condition that could confuse the assessment.
  • Subject with any other serious or unstable condition which in the opinion of the investigator might compromise participation in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
626 participants (actual)

Study arms

  • Experimental
    300 mg/day pregabalin (Lyrica)

    Patient take pregabalin capsule twice a day

    Drug: Pregabalin

  • Placebo comparator
    Placebo

    Drug: Placebo matched with pregabalin

Interventions

  • Subjects in the pregabalin group will start treatment with pregabalin capsule 150 mg/day for 1 week, then their dose will be increased to 300mg/day. After 1-week titration period, dose must be stable during study, no dose adjustment is permitted, and subject who cannot tolerate 300 mg/day pregabalin will be withdrawn. At the completion of the dose maintenance phase subjects will taper off study medication over a 1-week period. 300 mg/ day subjects will taper to 150 mg/ day.

  • DrugPlacebo matched with pregabalin

    Subject will take placebo matched with pregabalin twice a day.

06

What researchers measure

Primary outcomes

  1. Baseline Mean Pain Score

    The daily pain rating scale (DPRS) consists of an 11-point numeric scale ranging from 0 (no pain) to 10 (worst possible pain). Participants described their pain during the past 24 hours by choosing the appropriate number between 0 and 10.

    Time frame: Baseline

  2. Change From Baseline in Mean Pain Score at Endpoint

    The daily pain rating scale (DPRS) consists of an 11-point numeric scale ranging from 0 (no pain) to 10 (worst possible pain). Participants described their pain during the past 24 hours by choosing the appropriate number between 0 and 10. The mean endpoint pain score was obtained from the last 7 available DPRS scores of the daily pain diary while the participant was on study medication, up to and including the day after the last Week 8 (Day 57) dose.

    Time frame: Baseline and end of fixed dose phase (Day 63/Week 9)/Early Termination (Study Endpoint)

Secondary outcomes

  1. Change From Baseline in Weekly Mean Pain Score at Weeks 1 to 9

    The DPRS consists of an 11-point numeric scale ranging from 0 (no pain) to 10 (worst possible pain). Participants described their pain during the past 24 hours by choosing the appropriate number between 0 and 10. The weekly mean pain score was the sum of the daily scores divided by the number of diary entries during that week. The overall change is the average change from Weeks 1 to 9.

    Time frame: Baseline and weekly from Weeks 1 to 9

  2. Baseline Mean Sleep Interference Score

    Pain-related sleep interference was assessed on an 11-point numerical rating scale ranging from 0 (did not interfere with sleep) to 10 (completely interfered \[unable to sleep due to pain\]). Participants were to describe how their pain had interfered with their sleep during the past 24 hours by choosing the appropriate number between 0 and 10.

    Time frame: Baseline

  3. Change From Baseline in Mean Sleep Interference Score at Endpoint

    Pain-related sleep interference was assessed on an 11-point numerical rating scale ranging from 0 (did not interfere with sleep) to 10 (completely interfered \[unable to sleep due to pain\]). Participants were to describe how their pain had interfered with their sleep during the past 24 hours by choosing the appropriate number between 0 and 10. The mean endpoint score was obtained from the last 7 available scores of the daily diary while the participant was on study medication, up to and including the day after the last Week 9 (Day 63) dose.

    Time frame: Baseline and end of fixed dose phase (Day 63/Week 9)/Early Termination (Study Endpoint)

  4. Change From Baseline in Weekly Mean Sleep Interference Score at Weeks 1 to 9

    Pain-related sleep interference was assessed on an 11-point numerical rating scale ranging from 0 (did not interfere with sleep) to 10 (completely interfered \[unable to sleep due to pain\]). Participants were to describe how their pain had interfered with their sleep during the past 24 hours by choosing the appropriate number between 0 and 10. The weekly mean score was the sum of the daily scores divided by the number of diary entries during that week. The overall change is the average change from Weeks 1 to 9.

    Time frame: Baseline and weekly from Weeks 1 to 9

  5. Percentage of 30 Percent (%) Responders at Endpoint

    The DPRS consists of an 11-point numeric scale ranging from 0 (no pain) to 10 (worst possible pain). Participants described their pain during the past 24 hours by choosing the appropriate number between 0 and 10. A 30% responder was a participant who had 30% reduction or more in mean pain score at the end of the fixed dose phase (Day 63/Week 9) (Study Endpoint) compared to baseline.

    Time frame: End of fixed dose phase (Day 63/Week 9)/Early Termination (Study Endpoint)

  6. Change From Baseline in Short Form McGill Pain Questionnaire (SF-MPQ) Score at Weeks 1, 5, and 9

    SF-MPQ was assessed according to the participant's answer to the SF-MPQ questionnaire. The score for each composite scale (sensory, affective, and total) was derived by summing the reported intensity value for each item within a particular scale where None=0, Mild=1, Moderate=2, and Severe=3. The sensory score was the sum of the scores of the first 11 pain descriptors (throbbing, shooting, stabbing, sharp, cramping, gnawing, hot-burning, aching, heavy, tender, and splitting) and could range from 0-33. The affective score was the sum of the scores of the last 4 pain descriptors (tiring-exhausting, sickening, fearful, and punishing-cruel) and could range from 0-12. The total score was the sum of the scores of all 15 pain descriptors and could range from 0 to 45. Higher scores indicated greater pain.

    Time frame: Baseline; Weeks 1, 5, and 9

  7. Baseline Pain Visual Analogue Scale (VAS) and Present Pain Intensity (PPI) Scale

    The VAS was part of the Short Form McGill Pain Questionnaire (SF-MPQ) scale and reflected the overall pain intensity score, The pain VAS was a horizontal line; 100 millimeters (mm) in length, was self-administered by the participant in order to rate pain from 0 (no pain) to 100 (worst possible pain). The PPI was part of the SF-MPQ scale and measured the participant's present pain intensity on a 6-point scale ranging from 0 (no pain) to 5 (excruciating).

    Time frame: Baseline

  8. Change From Baseline in Pain VAS From the SF-MPQ at Endpoint

    The VAS was part of the SF-MPQ scale and reflected the overall pain intensity score. The pain VAS was a horizontal line; 100 mm in length, was self-administered by the participant in order to rate pain from 0 (no pain) to 100 (worst possible pain).

    Time frame: Baseline and Day 63 (Week 9)/Early Termination (Study Endpoint)

  9. Change From Baseline in PPI Scale From the SF-MPQ at Endpoint

    The PPI was part of the SF-MPQ scale and measured the participant's present pain intensity on a 6-point scale ranging from 0 (no pain) to 5 (excruciating).

    Time frame: Baseline and Day 63 (Week 9)/Early Termination (Study Endpoint)

  10. Baseline Medical Outcomes Study (MOS)-Sleep Scale Scores

    The MOS-Sleep Scale was a participant-rated instrument which assesses sleep quantity and quality with 12 items (7 subscale scores: sleep disturbance, snoring, awakening short of breath/with headache, sleep adequacy, somnolence, sleep quantity, optimal sleep; and a 9-item overall sleep problems index). Subscale scores total range: 0-100 (except sleep quantity \[range 0-24 hours\], optimal sleep \[yes:1, no:0\]). Higher scores=poorer sleep outcomes (except sleep quantity, adequacy, and optimal sleep).

    Time frame: Baseline

  11. Change From Baseline in MOS-Sleep Scale, Sleep Disturbance Score at Endpoint

    The MOS-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assessed key constructs of sleep. Instrument scoring yielded 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. The total score ranged from 0 to 100. For sleep disturbance, the subscale score also ranged from 0 to 100, with higher scores representing greater sleep disturbance.

    Time frame: Baseline and Day 63 (Week 9)/Early Termination (Study Endpoint)

  12. Change From Baseline in MOS-Sleep Scale, Snoring Score at Endpoint

    The MOS-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assessed key constructs of sleep. Instrument scoring yielded 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. The total score ranged from 0 to 100. The snoring subscale score also ranged from 0 to 100, with lower scores indicating less snoring.

    Time frame: Baseline and Day 63 (Week 9)/Early Termination (Study Endpoint)

  13. Change From Baseline in MOS-Sleep Scale, Awaken Short of Breath Score at Endpoint

    The MOS-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assessed key constructs of sleep. Instrument scoring yielded 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. The total score ranged from 0 to 100. The awaken short of breath subscale also ranged from 0 to 100, with lower scores indicating less difficulty in breathing.

    Time frame: Baseline and Day 63 (Week 9)/Early Termination (Study Endpoint)

  14. Change From Baseline in MOS-Sleep Scale, Quantity of Sleep Score at Endpoint

    The MOS-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assessed key constructs of sleep. Instrument scoring yielded 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. The total score ranged from 0 to 100. The MOS Sleep Quantity sub-scale scores ranged from 0 to 24 (number of hours slept).

    Time frame: Baseline and Day 63 (Week 9)/Early Termination (Study Endpoint)

  15. Percentage of Participants Who Had Optimal Sleep at Endpoint

    The MOS-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assessed key constructs of sleep. Instrument scoring yielded 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. The total score ranged from 0 to 100. The MOS optimal sleep subscale was a binary outcome derived from the sleep quantity responses: the response was YES if sleep quantity was 7 or 8 hours per night.

    Time frame: Day 63 (Week 9)/Early Termination (Study Endpoint)

  16. Change From Baseline in MOS-Sleep Scale, Sleep Adequacy Score at Endpoint

    The MOS-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assessed key constructs of sleep. Instrument scoring yielded 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. The total score ranged from 0 to 100. The sleep adequacy subscale also ranged from 0 to 100, with higher scores indicating greater sleep adequacy.

    Time frame: Baseline and Day 63 (Week 9)/Early Termination (Study Endpoint)

  17. Change From Baseline in MOS-Sleep Scale, Somnolence Score at Endpoint

    The MOS-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assessed key constructs of sleep. Instrument scoring yielded 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. The total score ranged from 0 to 100. The somnolence subscale score also ranged from 0 to 100, with lower scores indicating less somnolence.

    Time frame: Baseline and Day 63 (Week 9)/Early Termination (Study Endpoint)

  18. Change From Baseline in MOS-Sleep Scale, Sleep Problems Index Score at Endpoint

    The MOS-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assessed key constructs of sleep. Instrument scoring yielded 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. The total score ranged from 0 to 100. The sleep problems index subscale score also ranged from 0 to 100, with lower scores indicating fewer sleep problems.

    Time frame: Baseline and Day 63 (Week 9)/Early Termination (Study Endpoint)

  19. Clinical Global Impression of Change (CGIC) at Endpoint

    The CGIC was a clinician-rated global measure that provided a clinically relevant and easy to interpret account of a clinician's perception of the clinical importance of the participant's improvement or worsening during their involvement in a clinical study. Clinicians rated the participant's overall improvement on a 7-point scale where scores ranged from 1 (very much improved) to 7 (very much worse).

    Time frame: Day 63 (Week 9)/Early Termination (Study Endpoint)

  20. Patient Global Impression of Change (PGIC) Score at Endpoint

    The PGIC was a participant-rated global measure that provided a clinically relevant and easy to interpret account of a participant's perception of the clinical importance of their own improvement or worsening during their involvement in a clinical study. Participants rated their overall improvement on a 7-point scale where scores ranged from 1 (very much improved) to 7 (very much worse).

    Time frame: Day 63 (Week 9)/Early Termination (Study Endpoint)

  21. Baseline Hospital Anxiety and Depression Scale (HADS) Scores

    The HADS was a self-administered questionnaire that consisted of 2 subscales, 1 measuring anxiety (HADS-A Scale) and the other measuring depression (HADS-D Scale). Each subscale comprised of 7 items; participants assessed how each item applied to them on a scale of 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Subscores from HADS-A (Anxiety) and HADS-D (Depression) were not to be combined. The interpretation of each HADS subscales was as follows: 0-7 normal, 8-10 mild, 11-14 moderate and 15-21 severe.

    Time frame: Baseline

  22. Change From Baseline in HADS Anxiety Total Score at Endpoint

    The HADS was a self-administered questionnaire that consisted of 2 subscales, 1 measuring anxiety (HADS-A Scale) and the other measuring depression (HADS-D Scale). Each subscale was comprised of 7 items; participants assessed how each item applied to them on a scale of 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Subscores from HADS-A (Anxiety) and HADS-D (Depression) were not to be combined. The interpretation of each HADS subscales was as follows: 0-7 normal, 8-10 mild, 11-14 moderate and 15-21 severe.

    Time frame: Baseline and Day 63 (Week 9)/Early Termination (Study Endpoint)

  23. Change From Baseline in HADS Depression Total Score at Endpoint

    The HADS was a self-administered questionnaire that consisted of 2 subscales, 1 measuring anxiety (HADS-A Scale) and the other measuring depression (HADS-D Scale). Each subscale was comprised of 7 items; participants assessed how each item applied to them on a scale of 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Subscores from HADS-A (Anxiety) and HADS-D (Depression) were not to be combined. The interpretation of each HADS subscales was as follows: 0-7 normal, 8-10 mild, 11-14 moderate and 15-21 severe.

    Time frame: Baseline and Day 63 (Week 9)/Early Termination (Study Endpoint)

07

Results

Posted Jun 19, 2015

Participant flow

All participants were Chinese. 626 participants were randomized initially, as originally stated on clinicaltrials.gov. However, 3 participants discontinued right after randomization without any treatment information. As such, the actual number of participants randomized and assigned to treatment was 623 as stated in the "Started" Row below.

Participant flow — Overall Study
MilestonePregabalinPlacebo
Started314309
Treated313307
Completed284271
Not completed3038
Withdrew: Adverse event119
Withdrew: Other unspecified57
Withdrew: Protocol violation13
Withdrew: Withdrawal by subject45
Withdrew: Lost to follow-up11
Withdrew: Insufficient clinical response47
Withdrew: Did not meet entrance criteria34
Withdrew: Randomized but not treated12

Outcome measures

PrimaryBaseline Mean Pain Score

The daily pain rating scale (DPRS) consists of an 11-point numeric scale ranging from 0 (no pain) to 10 (worst possible pain). Participants described their pain during the past 24 hours by choosing the appropriate number between 0 and 10.

Time frame:
Baseline
Reported as:
Mean · units on a scale
Baseline Mean Pain Score
units on a scalePregabalinPlacebo
Baseline Mean Pain Score6.65 ± 1.1176.67 ± 1.150
PrimaryChange From Baseline in Mean Pain Score at Endpoint

The daily pain rating scale (DPRS) consists of an 11-point numeric scale ranging from 0 (no pain) to 10 (worst possible pain). Participants described their pain during the past 24 hours by choosing the appropriate number between 0 and 10. The mean endpoint pain score was obtained from the last 7 available DPRS scores of the daily pain diary while the participant was on study medication, up to and including the day after the last Week 8 (Day 57) dose.

Time frame:
Baseline and end of fixed dose phase (Day 63/Week 9)/Early Termination (Study Endpoint)
Reported as:
Least squares mean · units on a scale
Change From Baseline in Mean Pain Score at Endpoint
units on a scalePregabalinPlacebo
Change From Baseline in Mean Pain Score at Endpoint-2.14 ± 0.115-1.86 ± 0.117
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · p = 0.0559 (Primary analysis was two-sided and performed at the 0.05 significance level. No multiple comparisons adjustment was made.) · Least squares (ls) mean difference: -0.28 · 95% CI -0.58 to 0.01The ANCOVA model included treatment and study center as factors and the corresponding baseline score as a covariate in the model.
SecondaryChange From Baseline in Weekly Mean Pain Score at Weeks 1 to 9

The DPRS consists of an 11-point numeric scale ranging from 0 (no pain) to 10 (worst possible pain). Participants described their pain during the past 24 hours by choosing the appropriate number between 0 and 10. The weekly mean pain score was the sum of the daily scores divided by the number of diary entries during that week. The overall change is the average change from Weeks 1 to 9.

Time frame:
Baseline and weekly from Weeks 1 to 9
Reported as:
Least squares mean · units on a scale
Change From Baseline in Weekly Mean Pain Score at Weeks 1 to 9
units on a scalePregabalinPlacebo
Week 1 change from baseline (N=312, 307)-0.60 ± 0.091-0.36 ± 0.092
Week 2 change from baseline (N=304, 295)-0.97 ± 0.092-0.71 ± 0.093
Week 3 change from baseline (N=298, 291)-1.25 ± 0.092-1.01 ± 0.093
Week 4 change from baseline (N=297, 289)-1.47 ± 0.092-1.21 ± 0.093
Week 5 change from baseline (N=296, 287)-1.61 ± 0.092-1.39 ± 0.093
Week 6 change from baseline (N=293, 278)-1.84 ± 0.092-1.59 ± 0.094
Week 7 change from baseline (N=290, 275)-2.04 ± 0.092-1.77 ± 0.094
Week 8 change from baseline (N=290, 275)-2.18 ± 0.092-1.88 ± 0.094
Week 9 change from baseline (N=287, 273)-2.32 ± 0.092-2.07 ± 0.094
Overall change from baseline-1.59 ± 0.082-1.33 ± 0.083
Statistical analysis
  • Pregabalin vs Placebo · Mixed Model Repeated Measures Analysis · p = 0.0527 (All analyses were two-sided and performed at the 0.05 significance level.) · Ls mean difference: -0.23 · 95% CI -0.47 to 0.00
  • Pregabalin vs Placebo · Mixed Model Repeated Measures Analysis · p = 0.0279 (All analyses were two-sided and performed at the 0.05 significance level.) · Ls mean difference: -0.27 · 95% CI -0.50 to -0.03
  • Pregabalin vs Placebo · Mixed Model Repeated Measures Analysis · p = 0.0508 (All analyses were two-sided and performed at the 0.05 significance level.) · Ls mean difference: -0.24 · 95% CI -0.48 to 0.00
  • Pregabalin vs Placebo · Mixed Model Repeated Measures Analysis · p = 0.0349 (All analyses were two-sided and performed at the 0.05 significance level.) · Ls mean difference: -0.26 · 95% CI -0.49 to -0.02
  • Pregabalin vs Placebo · Mixed Model Repeated Measures Analysis · p = 0.0672 (All analyses were two-sided and performed at the 0.05 significance level.) · Ls mean difference: -0.22 · 95% CI -0.46 to 0.02
  • Pregabalin vs Placebo · Mixed Model Repeated Measures Analysis · p = 0.0469 (All analyses were two-sided and performed at the 0.05 significance level.) · Ls mean difference: -0.24 · 95% CI -0.48 to -0.00
  • Pregabalin vs Placebo · Mixed Model Repeated Measures Analysis · p = 0.0280 (All analyses were two-sided and performed at the 0.05 significance level.) · Ls mean difference: -0.27 · 95% CI -0.51 to -0.03
  • Pregabalin vs Placebo · Mixed Model Repeated Measures Analysis · p = 0.0140 (All analyses were two-sided and performed at the 0.05 significance level.) · Ls mean difference: -0.30 · 95% CI -0.54 to -0.06
  • Pregabalin vs Placebo · Mixed Model Repeated Measures Analysis · p = 0.0375 (All analyses were two-sided and performed at the 0.05 significance level.) · Ls mean difference: -0.25 · 95% CI -0.49 to -0.01
  • Pregabalin vs Placebo · Mixed Model Repeated Measures Analysis · p = 0.0164 (All analyses were two-sided and performed at the 0.05 significance level.) · Ls mean difference: -0.25 · 95% CI -0.46 to -0.05Overall change was estimated from the mixed effect model treatment main effect.
SecondaryBaseline Mean Sleep Interference Score

Pain-related sleep interference was assessed on an 11-point numerical rating scale ranging from 0 (did not interfere with sleep) to 10 (completely interfered \[unable to sleep due to pain\]). Participants were to describe how their pain had interfered with their sleep during the past 24 hours by choosing the appropriate number between 0 and 10.

Time frame:
Baseline
Reported as:
Mean · units on a scale
Baseline Mean Sleep Interference Score
units on a scalePregabalinPlacebo
Baseline Mean Sleep Interference Score5.25 ± 2.2365.12 ± 2.278
SecondaryChange From Baseline in Mean Sleep Interference Score at Endpoint

Pain-related sleep interference was assessed on an 11-point numerical rating scale ranging from 0 (did not interfere with sleep) to 10 (completely interfered \[unable to sleep due to pain\]). Participants were to describe how their pain had interfered with their sleep during the past 24 hours by choosing the appropriate number between 0 and 10. The mean endpoint score was obtained from the last 7 available scores of the daily diary while the participant was on study medication, up to and including the day after the last Week 9 (Day 63) dose.

Time frame:
Baseline and end of fixed dose phase (Day 63/Week 9)/Early Termination (Study Endpoint)
Reported as:
Least squares mean · units on a scale
Change From Baseline in Mean Sleep Interference Score at Endpoint
units on a scalePregabalinPlacebo
Change From Baseline in Mean Sleep Interference Score at Endpoint-1.52 ± 0.110-1.30 ± 0.112
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · p = 0.1340 (Analysis was two-sided and performed at the 0.05 significance level.) · Ls mean difference: -0.21 · 95% CI -0.49 to 0.07The ANCOVA model included treatment and study center as factors and the corresponding baseline score as a covariate in the model.
SecondaryChange From Baseline in Weekly Mean Sleep Interference Score at Weeks 1 to 9

Pain-related sleep interference was assessed on an 11-point numerical rating scale ranging from 0 (did not interfere with sleep) to 10 (completely interfered \[unable to sleep due to pain\]). Participants were to describe how their pain had interfered with their sleep during the past 24 hours by choosing the appropriate number between 0 and 10. The weekly mean score was the sum of the daily scores divided by the number of diary entries during that week. The overall change is the average change from Weeks 1 to 9.

Time frame:
Baseline and weekly from Weeks 1 to 9
Reported as:
Least squares mean · units on a scale
Change From Baseline in Weekly Mean Sleep Interference Score at Weeks 1 to 9
units on a scalePregabalinPlacebo
Week 1 change from baseline (N=311, 307)-0.38 ± 0.096-0.26 ± 0.098
Week 2 change from baseline (N=303, 295)-0.66 ± 0.097-0.51 ± 0.098
Week 3 change from baseline (N=297, 291)-0.88 ± 0.097-0.72 ± 0.099
Week 4 change from baseline (N=296, 289)-1.06 ± 0.097-0.86 ± 0.099
Week 5 change from baseline (N=295, 287)-1.14 ± 0.097-0.98 ± 0.099
Week 6 change from baseline (N=292, 278)-1.32 ± 0.098-1.07 ± 0.099
Week 7 change from baseline (N=289, 275)-1.43 ± 0.098-1.25 ± 0.099
Week 8 change from baseline (N=289, 275)-1.59 ± 0.098-1.36 ± 0.099
Week 9 change from baseline (N=286, 273)-1.67 ± 0.098-1.49 ± 0.100
Overall change from baseline-1.13 ± 0.085-0.94 ± 0.087
Statistical analysis
  • Pregabalin vs Placebo · Mixed Model Repeated Measures Analysis · p = 0.3438 (Analysis was two-sided and performed at the 0.05 significance level.) · Ls mean difference: -0.12 · 95% CI -0.37 to 0.13
  • Pregabalin vs Placebo · Mixed Model Repeated Measures Analysis · p = 0.2482 (Analysis was two-sided and performed at the 0.05 significance level.) · Ls mean difference: -0.15 · 95% CI -0.40 to 0.10
  • Pregabalin vs Placebo · Mixed Model Repeated Measures Analysis · p = 0.2249 (Analysis was two-sided and performed at the 0.05 significance level.) · Ls mean difference: -0.16 · 95% CI -0.41 to 0.10
  • Pregabalin vs Placebo · Mixed Model Repeated Measures Analysis · p = 0.1094 (Analysis was two-sided and performed at the 0.05 significance level.) · Ls mean difference: -0.21 · 95% CI -0.46 to 0.05
  • Pregabalin vs Placebo · Mixed Model Repeated Measures Analysis · p = 0.2095 (Analysis was two-sided and performed at the 0.05 significance level.) · Ls mean difference: -0.16 · 95% CI -0.41 to 0.09
  • Pregabalin vs Placebo · Mixed Model Repeated Measures Analysis · p = 0.0531 (Analysis was two-sided and performed at the 0.05 significance level.) · Ls mean difference: -0.25 · 95% CI -0.50 to 0.00
  • Pregabalin vs Placebo · Mixed Model Repeated Measures Analysis · p = 0.1628 (Analysis was two-sided and performed at the 0.05 significance level.) · Ls mean difference: -0.18 · 95% CI -0.44 to 0.07
  • Pregabalin vs Placebo · Mixed Model Repeated Measures Analysis · p = 0.0770 (Analysis was two-sided and performed at the 0.05 significance level.) · Ls mean difference: -0.23 · 95% CI -0.48 to 0.02
  • Pregabalin vs Placebo · Mixed Model Repeated Measures Analysis · p = 0.1651 (Analysis was two-sided and performed at the 0.05 significance level.) · Ls mean difference: -0.18 · 95% CI -0.43 to 0.07
  • Pregabalin vs Placebo · Mixed Model Repeated Measures Analysis · p = 0.1006 (Analysis was two-sided and performed at the 0.05 significance level.) · Ls mean difference: -0.18 · 95% CI -0.40 to 0.04
SecondaryPercentage of 30 Percent (%) Responders at Endpoint

The DPRS consists of an 11-point numeric scale ranging from 0 (no pain) to 10 (worst possible pain). Participants described their pain during the past 24 hours by choosing the appropriate number between 0 and 10. A 30% responder was a participant who had 30% reduction or more in mean pain score at the end of the fixed dose phase (Day 63/Week 9) (Study Endpoint) compared to baseline.

Time frame:
End of fixed dose phase (Day 63/Week 9)/Early Termination (Study Endpoint)
Reported as:
Number · percentage of participants
Percentage of 30 Percent (%) Responders at Endpoint
percentage of participantsPregabalinPlacebo
Percentage of 30 Percent (%) Responders at Endpoint50.3 ± 0.11544.3 ± 0.117
Statistical analysis
  • Pregabalin vs Placebo · Cochran-Mantel-Haenszel · p = 0.1309 (Analysis was two-sided and performed at the 0.05 significance level.) · Odds ratio (or): 1.27 · 95% CI 0.93 to 1.74Cochran-Mantel-Haenszel test comparing pregabalin to placebo adjusted for center.
SecondaryChange From Baseline in Short Form McGill Pain Questionnaire (SF-MPQ) Score at Weeks 1, 5, and 9

SF-MPQ was assessed according to the participant's answer to the SF-MPQ questionnaire. The score for each composite scale (sensory, affective, and total) was derived by summing the reported intensity value for each item within a particular scale where None=0, Mild=1, Moderate=2, and Severe=3. The sensory score was the sum of the scores of the first 11 pain descriptors (throbbing, shooting, stabbing, sharp, cramping, gnawing, hot-burning, aching, heavy, tender, and splitting) and could range from 0-33. The affective score was the sum of the scores of the last 4 pain descriptors (tiring-exhausting, sickening, fearful, and punishing-cruel) and could range from 0-12. The total score was the sum of the scores of all 15 pain descriptors and could range from 0 to 45. Higher scores indicated greater pain.

Time frame:
Baseline; Weeks 1, 5, and 9
Reported as:
Mean · units on a scale
Change From Baseline in Short Form McGill Pain Questionnaire (SF-MPQ) Score at Weeks 1, 5, and 9
units on a scalePregabalinPlacebo
Sensory score, Baseline (N=313, 306)7.90 ± 5.1018.11 ± 5.098
Sensory score, Week 1 change (N=311, 304)-1.50 ± 3.422-1.34 ± 3.134
Sensory score, Week 5 change (N=297, 288)-2.89 ± 4.244-2.47 ± 3.925
Sensory score, Week 9 change (N=288, 274)-3.87 ± 4.432-3.37 ± 4.348
Affective score, Baseline (N=313, 307)1.25 ± 1.8091.20 ± 1.817
Affective score, Week 1 change (N=311, 304)-0.41 ± 1.569-0.37 ± 1.410
Affective score, Week 5 change (N=297, 289)-0.72 ± 1.724-0.62 ± 1.652
Affective score, Week 9 change (N=287, 274)-0.75 ± 1.744-0.62 ± 1.792
Total score, Baseline (N=313, 307)9.15 ± 6.1189.28 ± 6.445
Total score, Week 1 change (N=311, 305)-1.92 ± 4.260-1.70 ± 3.908
Total score, Week 5 change (N=297, 289)-3.61 ± 5.084-3.07 ± 4.893
Total score, Week 9 change (N=288, 274)-4.62 ± 5.272-4.00 ± 5.512
SecondaryBaseline Pain Visual Analogue Scale (VAS) and Present Pain Intensity (PPI) Scale

The VAS was part of the Short Form McGill Pain Questionnaire (SF-MPQ) scale and reflected the overall pain intensity score, The pain VAS was a horizontal line; 100 millimeters (mm) in length, was self-administered by the participant in order to rate pain from 0 (no pain) to 100 (worst possible pain). The PPI was part of the SF-MPQ scale and measured the participant's present pain intensity on a 6-point scale ranging from 0 (no pain) to 5 (excruciating).

Time frame:
Baseline
Reported as:
Mean · units on a scale
Baseline Pain Visual Analogue Scale (VAS) and Present Pain Intensity (PPI) Scale
units on a scalePregabalinPlacebo
VAS69.08 ± 11.47469.06 ± 11.811
PPI2.28 ± 0.7842.27 ± 0.830
SecondaryChange From Baseline in Pain VAS From the SF-MPQ at Endpoint

The VAS was part of the SF-MPQ scale and reflected the overall pain intensity score. The pain VAS was a horizontal line; 100 mm in length, was self-administered by the participant in order to rate pain from 0 (no pain) to 100 (worst possible pain).

Time frame:
Baseline and Day 63 (Week 9)/Early Termination (Study Endpoint)
Reported as:
Least squares mean · units on a scale
Change From Baseline in Pain VAS From the SF-MPQ at Endpoint
units on a scalePregabalinPlacebo
Change From Baseline in Pain VAS From the SF-MPQ at Endpoint-25.07 ± 1.260-21.82 ± 1.279
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · p = 0.0463 (Analysis was two-sided and performed at the 0.05 significance level.) · Ls mean difference: -3.25 · 95% CI -6.45 to -0.05The ANCOVA model included treatment and study center as factors and the corresponding baseline score as a covariate in the model.
SecondaryChange From Baseline in PPI Scale From the SF-MPQ at Endpoint

The PPI was part of the SF-MPQ scale and measured the participant's present pain intensity on a 6-point scale ranging from 0 (no pain) to 5 (excruciating).

Time frame:
Baseline and Day 63 (Week 9)/Early Termination (Study Endpoint)
Reported as:
Least squares mean · units on a scale
Change From Baseline in PPI Scale From the SF-MPQ at Endpoint
units on a scalePregabalinPlacebo
Change From Baseline in PPI Scale From the SF-MPQ at Endpoint-0.80 ± 0.047-0.73 ± 0.048
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · p = 0.2748 (Analysis was two-sided and performed at the 0.05 significance level.) · Ls mean difference: -0.07 · 95% CI -0.19 to 0.05The ANCOVA model included treatment and study center as factors and the corresponding baseline score as a covariate in the model.
SecondaryBaseline Medical Outcomes Study (MOS)-Sleep Scale Scores

The MOS-Sleep Scale was a participant-rated instrument which assesses sleep quantity and quality with 12 items (7 subscale scores: sleep disturbance, snoring, awakening short of breath/with headache, sleep adequacy, somnolence, sleep quantity, optimal sleep; and a 9-item overall sleep problems index). Subscale scores total range: 0-100 (except sleep quantity \[range 0-24 hours\], optimal sleep \[yes:1, no:0\]). Higher scores=poorer sleep outcomes (except sleep quantity, adequacy, and optimal sleep).

Time frame:
Baseline
Reported as:
Mean · units on a scale
Baseline Medical Outcomes Study (MOS)-Sleep Scale Scores
units on a scalePregabalinPlacebo
Sleep disturbance score (N=313, 307)36.29 ± 24.76835.13 ± 26.915
Snoring score (N=312, 307)35.13 ± 36.67037.59 ± 37.163
Awaken short of breath score (N=313, 307)11.50 ± 21.55710.75 ± 21.883
Quantity of sleep score (N=311, 304)6.07 ± 2.8825.98 ± 1.451
Sleep adequacy score (N=313, 307)57.32 ± 31.51860.88 ± 30.274
Somnolence score (N=312, 307)33.87 ± 20.45936.03 ± 21.491
Sleep problems index score (N=312, 307)32.19 ± 19.80631.21 ± 20.388
SecondaryChange From Baseline in MOS-Sleep Scale, Sleep Disturbance Score at Endpoint

The MOS-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assessed key constructs of sleep. Instrument scoring yielded 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. The total score ranged from 0 to 100. For sleep disturbance, the subscale score also ranged from 0 to 100, with higher scores representing greater sleep disturbance.

Time frame:
Baseline and Day 63 (Week 9)/Early Termination (Study Endpoint)
Reported as:
Least squares mean · units on a scale
Change From Baseline in MOS-Sleep Scale, Sleep Disturbance Score at Endpoint
units on a scalePregabalinPlacebo
Change From Baseline in MOS-Sleep Scale, Sleep Disturbance Score at Endpoint-9.11 ± 1.222-7.98 ± 1.244
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · p = 0.4758 (Analysis was two-sided and performed at the 0.05 significance level.) · Ls mean difference: -1.13 · 95% CI -4.22 to 1.97The ANCOVA model included treatment and study center as factors and the corresponding baseline score as a covariate in the model.
SecondaryChange From Baseline in MOS-Sleep Scale, Snoring Score at Endpoint

The MOS-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assessed key constructs of sleep. Instrument scoring yielded 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. The total score ranged from 0 to 100. The snoring subscale score also ranged from 0 to 100, with lower scores indicating less snoring.

Time frame:
Baseline and Day 63 (Week 9)/Early Termination (Study Endpoint)
Reported as:
Least squares mean · units on a scale
Change From Baseline in MOS-Sleep Scale, Snoring Score at Endpoint
units on a scalePregabalinPlacebo
Change From Baseline in MOS-Sleep Scale, Snoring Score at Endpoint2.78 ± 1.716-0.53 ± 1.743
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · p = 0.1363 (Analysis was two-sided and performed at the 0.05 significance level.) · Ls mean difference: 3.31 · 95% CI -1.05 to 7.67The ANCOVA model included treatment and study center as factors and the corresponding baseline score as a covariate in the model.
SecondaryChange From Baseline in MOS-Sleep Scale, Awaken Short of Breath Score at Endpoint

The MOS-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assessed key constructs of sleep. Instrument scoring yielded 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. The total score ranged from 0 to 100. The awaken short of breath subscale also ranged from 0 to 100, with lower scores indicating less difficulty in breathing.

Time frame:
Baseline and Day 63 (Week 9)/Early Termination (Study Endpoint)
Reported as:
Least squares mean · units on a scale
Change From Baseline in MOS-Sleep Scale, Awaken Short of Breath Score at Endpoint
units on a scalePregabalinPlacebo
Change From Baseline in MOS-Sleep Scale, Awaken Short of Breath Score at Endpoint-2.10 ± 1.061-2.31 ± 1.078
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · p = 0.8808 (Analysis was two-sided and performed at the 0.05 significance level.) · Ls mean difference: 0.21 · 95% CI -2.49 to 2.90The ANCOVA model included treatment and study center as factors and the corresponding baseline score as a covariate in the model.
SecondaryChange From Baseline in MOS-Sleep Scale, Quantity of Sleep Score at Endpoint

The MOS-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assessed key constructs of sleep. Instrument scoring yielded 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. The total score ranged from 0 to 100. The MOS Sleep Quantity sub-scale scores ranged from 0 to 24 (number of hours slept).

Time frame:
Baseline and Day 63 (Week 9)/Early Termination (Study Endpoint)
Reported as:
Least squares mean · units on a scale
Change From Baseline in MOS-Sleep Scale, Quantity of Sleep Score at Endpoint
units on a scalePregabalinPlacebo
Change From Baseline in MOS-Sleep Scale, Quantity of Sleep Score at Endpoint0.33 ± 0.0850.14 ± 0.087
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · p = 0.0887 (Analysis was two-sided and performed at the 0.05 significance level.) · Ls mean difference: 0.19 · 95% CI -0.03 to 0.40The ANCOVA model included treatment and study center as factors and the corresponding baseline score as a covariate in the model.
SecondaryPercentage of Participants Who Had Optimal Sleep at Endpoint

The MOS-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assessed key constructs of sleep. Instrument scoring yielded 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. The total score ranged from 0 to 100. The MOS optimal sleep subscale was a binary outcome derived from the sleep quantity responses: the response was YES if sleep quantity was 7 or 8 hours per night.

Time frame:
Day 63 (Week 9)/Early Termination (Study Endpoint)
Reported as:
Number · percentage of participants
Percentage of Participants Who Had Optimal Sleep at Endpoint
percentage of participantsPregabalinPlacebo
Percentage of Participants Who Had Optimal Sleep at Endpoint43.8 ± 0.08545.0 ± 0.087
Statistical analysis
  • Pregabalin vs Placebo · Regression, Logistic · p = 0.7929 (Analysis was two-sided and performed at the 0.05 significance level.) · Odds ratio (or): 1.05 · 95% CI 0.72 to 1.53
SecondaryChange From Baseline in MOS-Sleep Scale, Sleep Adequacy Score at Endpoint

The MOS-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assessed key constructs of sleep. Instrument scoring yielded 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. The total score ranged from 0 to 100. The sleep adequacy subscale also ranged from 0 to 100, with higher scores indicating greater sleep adequacy.

Time frame:
Baseline and Day 63 (Week 9)/Early Termination (Study Endpoint)
Reported as:
Least squares mean · units on a scale
Change From Baseline in MOS-Sleep Scale, Sleep Adequacy Score at Endpoint
units on a scalePregabalinPlacebo
Change From Baseline in MOS-Sleep Scale, Sleep Adequacy Score at Endpoint8.87 ± 1.5327.82 ± 1.552
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · p = 0.5960 (Analysis was two-sided and performed at the 0.05 significance level.) · Ls mean difference: 1.05 · 95% CI -2.83 to 4.92The ANCOVA model included treatment and study center as factors and the corresponding baseline score as a covariate in the model.
SecondaryChange From Baseline in MOS-Sleep Scale, Somnolence Score at Endpoint

The MOS-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assessed key constructs of sleep. Instrument scoring yielded 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. The total score ranged from 0 to 100. The somnolence subscale score also ranged from 0 to 100, with lower scores indicating less somnolence.

Time frame:
Baseline and Day 63 (Week 9)/Early Termination (Study Endpoint)
Reported as:
Least squares mean · units on a scale
Change From Baseline in MOS-Sleep Scale, Somnolence Score at Endpoint
units on a scalePregabalinPlacebo
Change From Baseline in MOS-Sleep Scale, Somnolence Score at Endpoint-1.22 ± 1.187-0.88 ± 1.208
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · p = 0.8216 (Analysis was two-sided and performed at the 0.05 significance level.) · Ls mean difference: -0.35 · 95% CI -3.36 to 2.67The ANCOVA model included treatment and study center as factors and the corresponding baseline score as a covariate in the model.
SecondaryChange From Baseline in MOS-Sleep Scale, Sleep Problems Index Score at Endpoint

The MOS-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assessed key constructs of sleep. Instrument scoring yielded 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. The total score ranged from 0 to 100. The sleep problems index subscale score also ranged from 0 to 100, with lower scores indicating fewer sleep problems.

Time frame:
Baseline and Day 63 (Week 9)/Early Termination (Study Endpoint)
Reported as:
Least squares mean · units on a scale
Change From Baseline in MOS-Sleep Scale, Sleep Problems Index Score at Endpoint
units on a scalePregabalinPlacebo
Change From Baseline in MOS-Sleep Scale, Sleep Problems Index Score at Endpoint-6.71 ± 0.914-5.88 ± 0.927
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · p = 0.4829 (Analysis was two-sided and performed at the 0.05 significance level.) · Ls mean difference: -0.83 · 95% CI -3.14 to 1.49The ANCOVA model included treatment and study center as factors and the corresponding baseline score as a covariate in the model.
SecondaryClinical Global Impression of Change (CGIC) at Endpoint

The CGIC was a clinician-rated global measure that provided a clinically relevant and easy to interpret account of a clinician's perception of the clinical importance of the participant's improvement or worsening during their involvement in a clinical study. Clinicians rated the participant's overall improvement on a 7-point scale where scores ranged from 1 (very much improved) to 7 (very much worse).

Time frame:
Day 63 (Week 9)/Early Termination (Study Endpoint)
Reported as:
Least squares mean · units on a scale
Clinical Global Impression of Change (CGIC) at Endpoint
units on a scalePregabalinPlacebo
Clinical Global Impression of Change (CGIC) at Endpoint2.58 ± 0.0572.73 ± 0.058
Statistical analysis
  • Pregabalin vs Placebo · ANOVA · p = 0.0431 (Analysis was two-sided and performed at the 0.05 significance level.) · Ls mean difference: -0.15 · 95% CI -0.29 to -0.00
SecondaryPatient Global Impression of Change (PGIC) Score at Endpoint

The PGIC was a participant-rated global measure that provided a clinically relevant and easy to interpret account of a participant's perception of the clinical importance of their own improvement or worsening during their involvement in a clinical study. Participants rated their overall improvement on a 7-point scale where scores ranged from 1 (very much improved) to 7 (very much worse).

Time frame:
Day 63 (Week 9)/Early Termination (Study Endpoint)
Reported as:
Least squares mean · units on a scale
Patient Global Impression of Change (PGIC) Score at Endpoint
units on a scalePregabalinPlacebo
Patient Global Impression of Change (PGIC) Score at Endpoint2.60 ± 0.0572.74 ± 0.058
Statistical analysis
  • Pregabalin vs Placebo · ANOVA · p = 0.0602 (Analysis was two-sided and performed at the 0.05 significance level.) · Ls mean difference: -0.14 · 95% CI -0.28 to 0.01
SecondaryBaseline Hospital Anxiety and Depression Scale (HADS) Scores

The HADS was a self-administered questionnaire that consisted of 2 subscales, 1 measuring anxiety (HADS-A Scale) and the other measuring depression (HADS-D Scale). Each subscale comprised of 7 items; participants assessed how each item applied to them on a scale of 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Subscores from HADS-A (Anxiety) and HADS-D (Depression) were not to be combined. The interpretation of each HADS subscales was as follows: 0-7 normal, 8-10 mild, 11-14 moderate and 15-21 severe.

Time frame:
Baseline
Reported as:
Mean · units on a scale
Baseline Hospital Anxiety and Depression Scale (HADS) Scores
units on a scalePregabalinPlacebo
Anxiety total score3.76 ± 3.8003.67 ± 3.645
Depression total score4.45 ± 4.0814.35 ± 3.798
SecondaryChange From Baseline in HADS Anxiety Total Score at Endpoint

The HADS was a self-administered questionnaire that consisted of 2 subscales, 1 measuring anxiety (HADS-A Scale) and the other measuring depression (HADS-D Scale). Each subscale was comprised of 7 items; participants assessed how each item applied to them on a scale of 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Subscores from HADS-A (Anxiety) and HADS-D (Depression) were not to be combined. The interpretation of each HADS subscales was as follows: 0-7 normal, 8-10 mild, 11-14 moderate and 15-21 severe.

Time frame:
Baseline and Day 63 (Week 9)/Early Termination (Study Endpoint)
Reported as:
Least squares mean · units on a scale
Change From Baseline in HADS Anxiety Total Score at Endpoint
units on a scalePregabalinPlacebo
Change From Baseline in HADS Anxiety Total Score at Endpoint-0.48 ± 0.161-0.31 ± 0.163
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · p = 0.4172 (Analysis was two-sided and performed at the 0.05 significance level.) · Ls mean difference: -0.17 · 95% CI -0.57 to 0.24The ANCOVA model included treatment and study center as factors and the corresponding baseline score as a covariate in the model.
SecondaryChange From Baseline in HADS Depression Total Score at Endpoint

The HADS was a self-administered questionnaire that consisted of 2 subscales, 1 measuring anxiety (HADS-A Scale) and the other measuring depression (HADS-D Scale). Each subscale was comprised of 7 items; participants assessed how each item applied to them on a scale of 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Subscores from HADS-A (Anxiety) and HADS-D (Depression) were not to be combined. The interpretation of each HADS subscales was as follows: 0-7 normal, 8-10 mild, 11-14 moderate and 15-21 severe.

Time frame:
Baseline and Day 63 (Week 9)/Early Termination (Study Endpoint)
Reported as:
Least squares mean · units on a scale
Change From Baseline in HADS Depression Total Score at Endpoint
units on a scalePregabalinPlacebo
Change From Baseline in HADS Depression Total Score at Endpoint-0.57 ± 0.169-0.38 ± 0.172
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · p = 0.3724 (Analysis was two-sided and performed at the 0.05 significance level.) · Ls mean difference: -0.19 · 95% CI -0.62 to 0.23The ANCOVA model included treatment and study center as factors and the corresponding baseline score as a covariate in the model.

Adverse events

Collected over From Baseline till Week 10 (Day 70) and/or Early Termination.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pregabalin—7/314 (2.2%)77/314 (24.5%)
Placebo—5/308 (1.6%)55/308 (17.9%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventPregabalinPlacebo
Cerebral infarctionNervous system disorders1/3142/308
Spinal osteoarthritisMusculoskeletal and connective tissue disorders0/3141/308
InfectionInfections and infestations0/3141/308
GliomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3141/308
Hypoglycaemic comaNervous system disorders0/3141/308
Cardiac failureCardiac disorders1/3140/308
CataractEye disorders1/3140/308
GastroenteritisInfections and infestations1/3140/308
Basal ganglia haemorrhageNervous system disorders1/3140/308
Diabetic neuropathyNervous system disorders1/3140/308
Most frequent other events
Showing 10 of 12
Most frequent other events
EventPregabalinPlacebo
DizzinessNervous system disorders30/31412/308
SomnolenceNervous system disorders18/3146/308
Urinary tract infectionInfections and infestations7/31412/308
Oedema peripheralGeneral disorders10/3141/308
DiarrhoeaGastrointestinal disorders6/3147/308
Upper respiratory tract infectionInfections and infestations7/3146/308
NasopharyngitisInfections and infestations4/3146/308
HeadacheNervous system disorders4/3146/308
HyperuricaemiaMetabolism and nutrition disorders2/3145/308
NauseaGastrointestinal disorders5/3140/308

Baseline characteristics

The Full Analysis Set (FAS) was defined as all randomized participants who received at least 1 dose of study medication.

Age, Customized
Age, Customized(participants)PregabalinPlaceboTotal
18-44 years25 ± 10.315 ± 9.540
45-64 years172178350
More than or equal to (>=) 65 years116114230
Sex: Female, Male
Sex: Female, Male(Participants)PregabalinPlaceboTotal
Female159168327
Male154139293
08

Study locations

30 sites
  • Southwest hospital of the third military medical university/Department of Neurology
    Chongqing, Chongqing 400038, China
  • Fuzhou General Hospital of Nanjing Military Command
    Fuzhou, Fujian 350025, China
  • Department of Endocrinology, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
    Guangzhou, Guangdong 510120, China
  • The Second Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong 510260, China
  • Nanfang Hospital, Southern Medical University
    Guangzhou, Guangdong 510515, China
  • Dept. of Endocrinology, The first Affiliated Hospital of Harbin Medical University
    Harbin, Heilongjiang 150001, China
  • Dept. of Endocrinology, The second Affiliated Hospital of Harbin Medical University
    Harbin, Heilongjiang 150086, China
  • Tongji Hospital,Tongji Medical College Huazhong University of Science & Technology
    Wuhan, Hubei 430030, China
  • Xiangya Hospital of Centre-south University
    Changsha, Hunan 410008, China
  • Jiangsu Province Hospital
    Nanjing, Jiangsu 210029, China
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330006, China
  • Dept. of Endocrinology, The second hospital of Jilin University
    Changchun, Jilin 130041, China
  • Shengjing hospital of china medical university
    Shenyang, Liaoning 110004, China
  • Qilu Hospital of Shandong University/department of internal neurology
    Jinan, Shandong 250012, China
  • Qilu Hospital of Shandong University
    Jinan, Shandong 250012, China
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin 300052, China
  • The Second Affiliated Hospital Zhejiang University College of Medicine
    Hangzhou, Zhejiang 310009, China
  • Sir Run Run Shaw Hospital, School of medicine, Zhejiang University
    Hangzhou, Zhejiang 310016, China
  • Beijing Tiantan Hospital affiliated to Capital Medical University, Neurology Department
    Beijing, 100050, China
  • Peking University Third Hospital
    Beijing, 100191, China
  • Endocrinology Department
    Beijing, 100700, China
  • Beijing Hospital of the Ministry of Health
    Beijing, 100730, China
  • Tongren Hospital Affiliated to Capital Medical University
    Beijing, 100730, China
  • Chinese PLA General Hospital
    Beijing, 100853, China
  • GuangZhou First Municipal People's Hospital
    Guangzhou, 510180, China
  • Huashan Hospital Affiliated Fudan University, Neurology Department
    Shang Hai, 200040, China
  • Shanghai Changzheng Hospital
    Shanghai, 200003, China
  • Shanghai Tenth People's Hospital/The Endocrinology Department
    Shanghai, 200072, China
  • Shanghai First People's Hospital
    Shanghai, 200080, China
  • Renji Hospital Shanghai Jiao Tong University School of Medicine/Neurology Department
    Shanghai, 200127, China
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2011, a primary completion of Apr 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2015, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2011
First posted
Apr 8, 2011
Start
Jul 2011
Primary completionActual
Apr 2014
CompletionActual
Jun 2014
Results first posted
Jun 19, 2015
Last update
Jan 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01332149
Responsible party
Sponsor
First posted
Apr 8, 2011
Start date
Jul 2011
Primary completion
Apr 2014
Completion
Jun 2014
Results posted
Jun 19, 2015
Last update
Jan 28, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion